Daniel Worrel, MD
Orthopaedic Surgery · Dallas, TXNPI 1720032477
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $88,906 of the $108,125 with a category attached, or 82.2%. Zimmer Biomet accounts for 84.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $91,427 and has fallen 98.5% since, to $1,350 in 2025. Among orthopaedic surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $1092.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$91K
- Pylant Medical$13K
- Arthrex$2K
- Stryker$1K
- Orthofix Medical, Inc.$112
- Johnson & Johnson$66
- plus $236 from 7 others
Across 1 payment — averaging $632,804 each. An ownership or investment interest held by the physician or an immediate family member.
- Zurimed Technologies Inc.$633K
What the payments were for
- Royalty or licence$88,90682%
- Consulting fees$1,5001%
- Speaking & faculty fees$750%
- Travel & lodging$2,6742%
- Food & beverage$3,0633%
- Education$11,90711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 10 | $91,085 |
| Pylant Medical | 26 | $13,232 |
| Arthrex | 36 | $2,289 |
| Stryker | 7 | $1,105 |
| Orthofix Medical, Inc. | 4 | $112 |
| Johnson & Johnson | 5 | $66 |
| Amgen | 3 | $53 |
| Bioventus LLC | 1 | $44 |
| Smith+Nephew | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Molnlycke Health Care US, LLC | 1 | $25 |
| Terumo BCT, Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,125 in reported general payments places this provider in the 90th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 58 | $1,942 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 114 | $1,152 |
| Diclofenac Sodium | 58 | $574 |
| Ondansetron Hcl | 83 | $470 |
| Tramadol Hcl | 47 | $187 |
| Gabapentin | 27 | $174 |
| Meloxicam | 26 | $108 |
| Methylprednisolone | 13 | $85 |
| Cephalexin | 34 | $75 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Dallas
- Richard JonesDallas$6.3M
- James BrodskyDallas$2.5M
- Sumant KrishnanDallas$1.9M
- Wayne BurkheadDallas$1.2M
- Bradford WaddellDallas$325K
- Jay MabreyDallas$310K
- Eddie LoDallas$276K
- Clinton BellDallas$261K
- Jesus ReyDallas$227K
- Stephen BurkhartSan Antonio$185.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.